<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="Published by Elsevier Ltd. pmcid: 7102587S1871-4021(20)30051-5 doi: 10.1016/j.dsx.2020.03.011 : Article" exact="Chloroquine" post="and hydroxychloroquine in the treatment of COVID-19 with or"/>
 <result pre="Elsevier Ltd. pmcid: 7102587S1871-4021(20)30051-5 doi: 10.1016/j.dsx.2020.03.011 : Article Chloroquine and" exact="hydroxychloroquine" post="in the treatment of COVID-19 with or without diabetes:"/>
 <result pre="been tried. In view of recent studies and discussion on" exact="chloroquine" post="and hydroxychloroquine (HCQ), we aimed to review existing literature"/>
 <result pre="In view of recent studies and discussion on chloroquine and" exact="hydroxychloroquine" post="(HCQ), we aimed to review existing literature and relevant"/>
 <result pre="March 21, 2020 and retrieved all the articles published on" exact="chloroquine" post="and HCQ and COVID-19. Results Two small human studies"/>
 <result pre="drugs have been tried for Coronavirus Disease-2019 (COVID-19). •Chloroquine and" exact="Hydroxychloroquine" post="has shown some promise in treatment of COVID-19 and"/>
 <result pre="and propose use of these drugs in COVID-19. Keywords COVID-19" exact="Chloroquine" post="Hydroxychloroquine Diabetes 1 Introduction Novel coronavirus (2019-nCoV), officially known"/>
 <result pre="propose use of these drugs in COVID-19. Keywords COVID-19 Chloroquine" exact="Hydroxychloroquine" post="Diabetes 1 Introduction Novel coronavirus (2019-nCoV), officially known as"/>
 <result pre="the treatment for COVID-19 that includes a low-cost antimalarial drug" exact="chloroquine" post="and its derivative hydroxychloroquine (HCQ), along with several other"/>
 <result pre="that includes a low-cost antimalarial drug chloroquine and its derivative" exact="hydroxychloroquine" post="(HCQ), along with several other antiviral drugs. Because HCQ"/>
 <result pre="[6] Table 1 Drugs Types Mechanisms of action Past evidences" exact="Chloroquine" post="4-aminoquinoline Not clearly known, changes the pH of endosomes"/>
 <result pre="by SARS-CoV-2 in vitro, approved for malaria treatment and prophylaxis" exact="Hydroxychloroquine" post="4-aminoquinoline Not clearly known, changes the pH of endosomes"/>
 <result pre="rheumatic diseases). Approved for treatment of T2DM in India Remdesivir" exact="Adenosine" post="nucleotide analogues Inhibits viral application Effective against SARS and"/>
 <result pre="nucleotide analogues Inhibits viral application Effective against SARS and MERS" exact="Ribavirin" post="Nucleoside analogue Inhibits viral RNA synthesis and mRNA capping"/>
 <result pre="mRNA capping No evidence in SARS (potential harm) and MERS" exact="Ribavirin" post="plus Interferon Inhibits viral replication Mixed result against MERS"/>
 <result pre="evidences that have emerged so far on the efficacy of" exact="chloroquine" post="and hydroxychloroquine, in the treatment of patients with COVID-19,"/>
 <result pre="PubMed database up till March 21, 2020 using key words" exact="chloroquine" post="AND COVID-19, and hydroxychloroquine AND COVID-19 and retrieved a"/>
 <result pre="March 21, 2020 using key words chloroquine AND COVID-19, and" exact="hydroxychloroquine" post="AND COVID-19 and retrieved a total of 13 articles."/>
 <result pre="both these compounds from ClinicalTrials.gov. 3 Results 3.1 Studies of" exact="chloroquine" post="and hydroxychloroquine conducted in vitro Experimental studies have suggested"/>
 <result pre="compounds from ClinicalTrials.gov. 3 Results 3.1 Studies of chloroquine and" exact="hydroxychloroquine" post="conducted in vitro Experimental studies have suggested that chloroquine"/>
 <result pre="and hydroxychloroquine conducted in vitro Experimental studies have suggested that" exact="chloroquine" post="is a proven anti-malarial drug that has the capability"/>
 <result pre="micro-organisms including coronaviruses in vitro. It is also believed that" exact="chloroquine" post="may have a varied mechanism of action which may"/>
 <result pre="been increasingly learnt that the anti-viral and anti-inflammatory activities of" exact="chloroquine" post="may have a role in the treatment of patients"/>
 <result pre="a role in the treatment of patients with novel COVID-19." exact="Chloroquine" post="increases endosomal pH and interferes with the glycosylation of"/>
 <result pre="has the potential to block viral infection [7]. In addition," exact="chloroquine" post="also inhibits the quinone reductase-2, which is involved in"/>
 <result pre="and orthomyxoviruses uses sialic acid moieties as a receptor. Moreover," exact="chloroquine" post="changes the pH of lysosomes and likely inhibits cathepsins,"/>
 <result pre="formation of the autophagosome which cleaves SARS-CoV-2 spike protein. Furthermore," exact="chloroquine" post="through the inhibition of MAP-kinase interferes with SARS-CoV-2 molecular"/>
 <result pre="M protein [7,8]. Previous experimental studies have also demonstrated that" exact="chloroquine" post="has potent anti-SARS-CoV-1 effects in vitro, primarily attributable to"/>
 <result pre="utilizes the similar surface receptor ACE2, it is believed that" exact="chloroquine" post="can also interfere with ACE2 receptor glycosylation thus prevents"/>
 <result pre="[7], [8], [9]]. Chinese researchers who studied the effect of" exact="chloroquine" post="in vitro (using Vero E6 cell line infected by"/>
 <result pre="vitro (using Vero E6 cell line infected by SARS-CoV-2) found" exact="chloroquine" post="to be highly effective in reducing viral replication that"/>
 <result pre="lung [6,10]. Since the structure and mechanism of action of" exact="chloroquine" post="and hydroxychloroquine (HCQ) are exactly same except an additional"/>
 <result pre="Since the structure and mechanism of action of chloroquine and" exact="hydroxychloroquine" post="(HCQ) are exactly same except an additional hydroxy moiety"/>
 <result pre="transport and the post-entry stages of SARS-CoV-2, similar to the" exact="chloroquine" post="and one study found HCQ to be a more"/>
 <result pre="study found HCQ to be a more potent agent than" exact="chloroquine" post="in inhibiting SARS-CoV-2 in vitro [12,13]. In addition, HCQ"/>
 <result pre="lesser risk of retinal toxicity with HCQ, as compared to" exact="chloroquine" post="[16]. Furthermore, the narrow therapeutic and safety index margin"/>
 <result pre="[16]. Furthermore, the narrow therapeutic and safety index margin with" exact="chloroquine" post="makes HCQ a safer option than chloroquine. An additional"/>
 <result pre="of HCQ with less drug-drug interactions. 3.2 Studies conducted with" exact="chloroquine" post="and hydroxychloroquine in human COVID-19 The anti-viral and anti-inflammatory"/>
 <result pre="with less drug-drug interactions. 3.2 Studies conducted with chloroquine and" exact="hydroxychloroquine" post="in human COVID-19 The anti-viral and anti-inflammatory actions of"/>
 <result pre="hydroxychloroquine in human COVID-19 The anti-viral and anti-inflammatory actions of" exact="chloroquine" post="have led to numerous trials urgently in the face"/>
 <result pre="Chinese study involving more than 100 patients of COVID-19 found" exact="chloroquine" post="superior to the control group in reducing symptom duration,"/>
 <result pre="[18]. This represents the first human trial ever conducted with" exact="chloroquine" post="against COVID-19. Although the detailed results of this trial"/>
 <result pre="letter form, interestingly, this early result led China to include" exact="chloroquine" post="in the prevention and treatment of COVID-19 pneumonia. Moreover,"/>
 <result pre="Commission of the People’s Republic of China recommended inclusion of" exact="chloroquine" post="in the next version of the Guidelines for the"/>
 <result pre="and Treatment of Pneumonia Caused by COVID-19. In this study," exact="chloroquine" post="was given in dose of 500 mg of chloroquine"/>
 <result pre="study, chloroquine was given in dose of 500 mg of" exact="chloroquine" post="twice daily in mild to severe COVID-19 pneumonia (see"/>
 <result pre="al. found that HCQ alone and combination of HCQ plus" exact="azithromycin" post="was highly and significantly effective in clearing viral nasopharyngeal"/>
 <result pre="(p &amp;lt; 0.001). This data suggests a synergistic effect of" exact="azithromycin" post="with HCQ. Indeed, azithromycin has shown an antiviral effect"/>
 <result pre="data suggests a synergistic effect of azithromycin with HCQ. Indeed," exact="azithromycin" post="has shown an antiviral effect against Zika and Ebola"/>
 <result pre="institutions and or organizations have already recognized the utility of" exact="chloroquine" post="and HCQ [20]. The expert consensus from the Department"/>
 <result pre="(based on in vitro evidence and still unpublished clinical experience)" exact="chloroquine" post="phosphate tablet at a dose of 500 mg twice"/>
 <result pre="Korea who have treated 27 cases of COVID-19 recommend using" exact="lopinavir" post="400mg/Ritonavir 100 mg BID or Chloroquine 500 mg orally"/>
 <result pre="of COVID-19 recommend using lopinavir 400mg/Ritonavir 100 mg BID or" exact="Chloroquine" post="500 mg orally per day or Hydroxychloroquine 400 mg"/>
 <result pre="mg BID or Chloroquine 500 mg orally per day or" exact="Hydroxychloroquine" post="400 mg orally per day for 7–10 days, in"/>
 <result pre="public document on its website, also suggested the use of" exact="chloroquine" post="in those having severe COVID-19 infection admitted in the"/>
 <result pre="of March 21, 2020) in the treatment of COVID-19 for" exact="Chloroquine" post="and Hydroxychloroquine.19,[21], [22], [23], [24], [25], [26], [27], [28]"/>
 <result pre="Science and Technology and Health Commission of Guangdong province, China21" exact="Chloroquine" post="phosphate 500 mg BID for 10 days. Central Clinical"/>
 <result pre="Korea22 Moderate to severe COVID-19:Lopinavir 400mg/Ritonavir 100 mg BID or" exact="Chloroquine" post="500 mg orally per day or Hydroxychloroquine 400 mg"/>
 <result pre="mg BID or Chloroquine 500 mg orally per day or" exact="Hydroxychloroquine" post="400 mg orally per day for 7–10 days. Centre"/>
 <result pre="days. The Dutch Center of Disease Control24 600 mg of" exact="Chloroquine" post="base followed by 300 mg after 12 h on"/>
 <result pre="and Tropical Diseases (Lombardy Section)25 Mild to moderate COVID-19:Lopinavir/ritonavir plus" exact="Chloroquine" post="500 mg × 2/day or Hydroxychloroquine 200 mg per"/>
 <result pre="to moderate COVID-19:Lopinavir/ritonavir plus Chloroquine 500 mg × 2/day or" exact="Hydroxychloroquine" post="200 mg per day for 10 days.Severe or critical"/>
 <result pre="mg per day for 10 days.Severe or critical COVID-19:Remdesivir plus" exact="Chloroquine" post="500 mg × 2/day or Hydroxychloroquine 200 mg per"/>
 <result pre="or critical COVID-19:Remdesivir plus Chloroquine 500 mg × 2/day or" exact="Hydroxychloroquine" post="200 mg per day for 10–20 days. Mount Sinai"/>
 <result pre="Insufficient evidence to issue a recommendation on the use of" exact="chloroquine" post="or hydroxychloroquine in critically ill adults with COVID-19 at"/>
 <result pre="to issue a recommendation on the use of chloroquine or" exact="hydroxychloroquine" post="in critically ill adults with COVID-19 at this point"/>
 <result pre="later followed by 300 mg BID for 5 days (Consider" exact="lopinavir" post="400 mg/ritonavir 100 mg BID for 14 days as"/>
 <result pre="14 days as a second choice only if HCQ and" exact="chloroquine" post="is contraindicated, provided it can be administered within 10"/>
 <result pre="days (lopinavir/ritonavir as second option)Critical COVID-19:Remdesivir for 10 days plus" exact="chloroquine" post="for 5 day Gautret et al., Marseille, France19 Hydroxychloroquine"/>
 <result pre="plus chloroquine for 5 day Gautret et al., Marseille, France19" exact="Hydroxychloroquine" post="200 mg TID for 10 days. OD-once daily, BID-twice"/>
 <result pre="reaction, i.v - intravenous. 4 Discussion The antiviral activity of" exact="chloroquine" post="and HCQ have been identified in the in vitro"/>
 <result pre="Zika virus and influenza A H5N1. However, no benefit of" exact="chloroquine" post="was seen in the prevention of influenza and dengue"/>
 <result pre="infection in a randomized, double-blind, placebo-controlled, clinical trial [29,30]. Similarly," exact="chloroquine" post="was active in ex vivo studies but not in"/>
 <result pre="ebolavirus, nipah and influenza viruses [[31], [32], [33]]. Data of" exact="chloroquine" post="against chikungunya virus is even more intriguing. While chloroquine"/>
 <result pre="of chloroquine against chikungunya virus is even more intriguing. While" exact="chloroquine" post="had satisfactory antiviral activity against chikungunya in vitro, animal"/>
 <result pre="of fever and incomplete viral clearance [34]. Human trials of" exact="chloroquine" post="showed no improvement in chikungunya acute illness and rather"/>
 <result pre="post-illness period, compared to the controls [35]. The role of" exact="chloroquine" post="against Human Immunodeficiency Virus was inconclusive [36]. The only"/>
 <result pre="Immunodeficiency Virus was inconclusive [36]. The only viral disease where" exact="chloroquine" post="was modestly effective so far before COVID-19 era was"/>
 <result pre="C suggesting an increased virological response to pegylated interferon plus" exact="ribavirin" post="[37]. Therefore, the results of chloroquine and HCQ so"/>
 <result pre="to pegylated interferon plus ribavirin [37]. Therefore, the results of" exact="chloroquine" post="and HCQ so far done against COVID-19, more promising"/>
 <result pre="countries where malaria is endemic. 4.1 Cautions and contraindication with" exact="chloroquine" post="and hydroxychloroquine Expectedly, some precautions will be needed while"/>
 <result pre="malaria is endemic. 4.1 Cautions and contraindication with chloroquine and" exact="hydroxychloroquine" post="Expectedly, some precautions will be needed while using both"/>
 <result pre="and moxifloxacin etc.) must be avoided [38,39]. Moreover, addition of" exact="azithromycin" post="to HCQ as done in French trial by Gautret"/>
 <result pre="with diabetes especially with concurrent use of chloroquine/HCQ and lopinavir/ritonavir." exact="Chloroquine" post="and HCQ should not be used concurrently with lopinavir/ritonavir"/>
 <result pre="maculopathy, G6PD deficiency, recent myocardial infarction and QTc &amp;gt;500 msec." exact="Chloroquine" post="is not contraindicated in pregnancy. 5 Conclusion Although evidence"/>
 <result pre="is not contraindicated in pregnancy. 5 Conclusion Although evidence of" exact="chloroquine" post="and HCQ is limited (based on the experimental data"/>
 <result pre="small human trials), considering the potentially favorable benefit-risk balance of" exact="chloroquine" post="and HCQ in absence of any other valid treatment"/>
 <result pre="of management in Table 3 . The low cost of" exact="chloroquine" post="and HCQ could also be an effective strategy to"/>
 <result pre="the benefit-risk ratio as well as the low cost of" exact="chloroquine" post="and hydroxychloroquine in Indian context, we propose the following"/>
 <result pre="ratio as well as the low cost of chloroquine and" exact="hydroxychloroquine" post="in Indian context, we propose the following regime, until"/>
 <result pre="of intervention Proposed Chemoprophylaxis •No conclusive evidence so far; however," exact="chloroquine" post="or HCQ could be researched as a prophylactic agent"/>
 <result pre="as compared to non-diabetic subjects with COVID-19. Confirmed COVID-19 A." exact="Chloroquine" post="phosphate: @$1. COVID-19 URTI: 500 mg BID for 5"/>
 <result pre="HCQ-hydroxychloroquine, BID – twice daily. Table 4 Ongoing trials with" exact="chloroquine" post="and hydroxychloroquine as of March 21, 2020. Table 4"/>
 <result pre="– twice daily. Table 4 Ongoing trials with chloroquine and" exact="hydroxychloroquine" post="as of March 21, 2020. Table 4 Study title"/>
 <result pre="ClinicalTrial.Org identifier Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and" exact="Chloroquine" post="for Treatment of COVID19: A Randomized Control Trial (THDMS-COVID19)"/>
 <result pre="COVID19: A Randomized Control Trial (THDMS-COVID19) Treatment Antiviral drugs plus" exact="Chloroquine" post="PBO 80 Thailand NCT04303299 Chloroquine Prevention of Coronavirus Disease"/>
 <result pre="(THDMS-COVID19) Treatment Antiviral drugs plus Chloroquine PBO 80 Thailand NCT04303299" exact="Chloroquine" post="Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting"/>
 <result pre="of Coronavirus Disease (COVID-19) in the Healthcare Setting (COPCOV) Prophylaxis" exact="Chloroquine" post="PBO 10,000 UK NCT04303507 Treatment of Mild Cases and"/>
 <result pre="(HCQ4COV19) Treatment and prophylaxis in two separate groups Darunavir/Cobicistat plus" exact="Chloroquine" post="PBO 3040 Germany NCT04304053 The Clinical Study of Carrimycin"/>
 <result pre="Carrimycin on Treatment Patients With COVID-19 Treatment Carrimycin Lopinavir/ritonavir Arbidol" exact="Chloroquine" post="PBO 520 China NCT04286503 Comparison of Lopinavir/Ritonavir or Hydroxychloroquine"/>
 <result pre="Arbidol Chloroquine PBO 520 China NCT04286503 Comparison of Lopinavir/Ritonavir or" exact="Hydroxychloroquine" post="in Patients with Mild Coronavirus Disease (COVID-19) Treatment Lopinavir/ritonavir"/>
 <result pre="Treatment Lopinavir/ritonavir HCQ 150 Korea NCT04307693 Efficacy and Safety of" exact="Hydroxychloroquine" post="for Treatment of Pneumonia Caused by 2019-nCoV (HC-nCoV) Treatment"/>
 <result pre="planned for COVID-19: Several trials are currently underway with both" exact="chloroquine" post="and HCQ in patients with COVID-19 at different doses."/>
 <result pre="ClinicalTrial.org database dated March 21, 2020 showed 4 trials with" exact="chloroquine" post="and 3 trials with HCQ which is currently under"/>
 <result pre="area which needs to be explored further is resistance to" exact="chloroquine" post="and HCQ that may be present with different strains"/>
 <result pre="for the 2019-new coronavirus (2019-nCoV)Biosci Trends2020 Jan 2810.5582/bst.2020.01020 7WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
 <result pre="severe acute respiratory syndrome coronavirus (SARS-CoV)J Biol Chem29120169218e3226953343 10ColsonP.RolainJ.M.LagierJ.C.BrouquiP.RaoultD.Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int J Antimicrob Agents2020"/>
 <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
 <result pre="Mar 910.1093/cid/ciaa237pii: ciaa237, [Epub ahead of print] 14RaoultD.DrancourtM.VestrisG.Bactericidal effect of" exact="doxycycline" post="associated with lysosomotropic agents on Coxiella burnetii in P388D1"/>
 <result pre="Antimicrob Agents. 16MarmorM.F.KellnerU.LaiT.Y.MellesR.B.MielerW.F.American academy of ophthalmology. Recommendations on screening for" exact="chloroquine" post="and hydroxychloroquine retinopathy2016Revision 17HuangC.WangY.LiX.RenL.ZhaoJ.HuY.Clinical features of patients infected with"/>
 <result pre="16MarmorM.F.KellnerU.LaiT.Y.MellesR.B.MielerW.F.American academy of ophthalmology. Recommendations on screening for chloroquine and" exact="hydroxychloroquine" post="retinopathy2016Revision 17HuangC.WangY.LiX.RenL.ZhaoJ.HuY.Clinical features of patients infected with 2019 novel"/>
 <result pre="24. Ophthalmology. 2016 Jun;123(6):1386-94. doi:10.1016/j.ophtha.2016.01.058. Epub 2016 Mar 1631986264 18GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
 <result pre="of COVID-19 associated pneumonia in clinical studiesBiosci Trends202010.5582/bst.2020.01047 19GautretP.LagieraJ.C.ParolaaP.HoangaV.T.MeddebaL.MailheaM.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open"/>
 <result pre="clinical trialInt J Antimicrob Agents17 March 202010.1016/j.ijantimicag.2020.105949In Press 20TouretF.de LamballerieX.Of" exact="chloroquine" post="and COVID-19Antivir Res1772020 Mar 510476210.1016/j.antiviral.2020.104762[Epub ahead of print]32147496 21Multicenter"/>
 <result pre="of Guangdong Province and Health Commission of Guangdong Province for" exact="chloroquine" post="in the treatment of novel coronavirus pneumonia. Expert consensus"/>
 <result pre="in the treatment of novel coronavirus pneumonia. Expert consensus on" exact="chloroquine" post="phosphate for the treatment of novel coronavirus pneumonia]Zhonghua Jiehe"/>
 <result pre="controlled trialLancet Infect Dis1192011 Sep67768321550310 30TricouV.MinhN.N.VanT.P.LeeS.J.FarrarJ.WillsB.A randomized controlled trial of" exact="chloroquine" post="for the treatment of dengue in Vietnamese adultsPLoS Neglected"/>
 <result pre="Neglected Trop Dis42010e78510.1371/journal.pntd.0000785 31FalzaranoD.SafronetzD.PrescottJ.MarziA.FeldmannF.FeldmannH.Lack of protection against ebola virus from" exact="chloroquine" post="in mice and hamstersEmerg Infect Dis2120151065106725988934 32VigerustD.J.McCullersJ.A.Chloroquine is effective"/>
 <result pre="in malaria-endemic areasAm J Trop Med Hyg61199918018610463664 35RoquesP.ThibervilleS.D.Dupuis-MaguiragaL.LumF.M.LabadieK.MartinonF.Paradoxical effect of" exact="chloroquine" post="treatment in enhancing chikungunya virus infectionViruses1052018 May 1710.3390/v10050268pii: E268"/>
 <result pre="May 1710.3390/v10050268pii: E268 36ChauhanA.TikooA.The enigma of the clandestine association between" exact="chloroquine" post="and HIV-1 infectionHIV Med16201558559026238012 37HelalG.K.GadM.A.Abd-EllahM.F.EidM.S.Hydroxychloroquine augments early virological response"/>
 <result pre="Med16201558559026238012 37HelalG.K.GadM.A.Abd-EllahM.F.EidM.S.Hydroxychloroquine augments early virological response to pegylated interferon plus" exact="ribavirin" post="in genotype-4 chronic hepatitis C patientsJ Med Virol881220162170217827183377 38Chloroquine"/>
 <result pre="39Chloroquine US prescribing information(Last accessed March 21, 2020)https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009768s037s045s047lbl.pdf 40LiuD.LiX.ZhangY.KwongJ.S.W.LiL.ZhangY.Chloroquine and" exact="hydroxychloroquine" post="are associated with reduced cardiovascular risk: a systematic review"/>
 <result pre="Ther12201816851695 41CortegianiA.IngogliaG.IppolitoM.GiarratanoA.EinavS.A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J Crit Care202020 Mar 10303903039710.1016/j.jcrc.2020.03.005pii:"/>
 <result pre="S0883-9441https://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infection.pdf[Epub ahead of print]. 42: Recommendations for empiric use of" exact="hydroxychloroquine" post="for prophylaxis of SARS CoV-2 infection"/>
</results>
